Radiology · 1998 · 244 citations · 0 references
MedicinePathologyRadiologyDiagnostic ImagingDiagnostic RadiologySpectroscopyBreast Cancer ImagingBreast ImagingBreast Lesion CharacterizationBreast PathologyMagnetic Resonance ImagingMagnetic Resonance Spectroscopy1D Proton Nuclear Magnetic Resonance SpectroscopyBenign Breast Disease EvaluationBreast Imaging FindingsBreast Lesion DiagnosisCholine ImagingMagnetic ResonanceMagnetic Resonance Imaging Lesion EvaluationSpectroscopic Imaging
PURPOSE: To assess the clinical usefulness of spatially localized hydrogen-1 magnetic resonance (MR) spectroscopy in distinguishing benign from malignant lesions on the basis of total choline levels. MATERIALS AND METHODS: These studies were performed at 1.5 T with a four-channel multicoil that compresses the breast sagittally. Contrast material-enhanced MR imaging and single-voxel H-1 MR spectroscopy were performed in 17 patients (age range, 25-68 years) who had nonspecific mammographic findings. Histopathologic correlations were made from biopsy or surgical specimens. Ten patients had various malignant breast lesions 1-4 cm in diameter, and seven patients had benign processes. RESULTS: Most studies were performed with nominal voxel sizes (< 2 cm3). Spectra obtained with an echo time of 31 msec showed resonances from water and mobile fatty acids and, in some cases, the N-trimethyl resonance of choline-containing compounds (Cho) at 3.2 ppm. The absolute concentration of Cho in each lesion was determined with a phantom containing 1 mmol/L Cho as an external reference. On the basis of reference measurements, the least detectable level of Cho was 0.2 mmol/L. With this threshold, seven of 10 malignant lesions showed detectable levels of Cho. In contrast, Cho was seen in only one patient with an extremely rare benign process, a tubular adenoma. The remaining six patients with benign processes demonstrated no detectable Cho levels. CONCLUSION: Spatially localized H-1 MR spectroscopy can provide sufficient sensitivity and spectral resolution at 1.5 T to demonstrate Cho in human breast lesions with a spectroscopic protocol that provides up to 1-cm3 resolution. Determining the presence of Cho may provide a useful test for malignancy.